Individual post hoc pegaspargase pharmacokinetic estimates day 14 activity, threshold time, Vmax , and CLint during continuation week 7 and week 17 differed by risk arm and randomized pegaspargase dosage levels. There were 84, 89, 82, and 96 patients in low risk (LR, intermittent dosing) 2500 U/m2, standard/high risk (SHR, continuous dosing) 2500 U/m2, LR 3500 U/m2, and SHR 3500 U/m2 group, respectively, for week 7; and 63, 74, 66, and 79 in LR 2500, SHR 2500, LR 3500, and SHR 3500 group, respectively, for week 17. In each plot, red P values compare between different randomized dosage levels within SHR patients; blue P values compare between different randomized dosage levels within LR patients. P values below each plot in black compare between different risk arms randomized to receive the same dosage level. All P values were generated using linear mixed-effect model adjusting for antibody status and clinical reaction. Only randomized patients were included in these analyses.